DR647RT) and counterstained with DAPI (blue; Lunaphore Catalog # DR100). Specific staining was localized to the membrane. Protocol available in COMET™ Panel Builder." alt="CD34 was detected in immersion fixed paraffin-embedded sections of mouse Thymus using Rat Anti-Mouse CD34, Monoclonal Antibody (Catalog #NB600-1071) at 1:500 dilution at 37 ° Celsius for 2 minutes. Before incubation with the primary antibody, tissue underwent an all-in-one dewaxing and antigen retrieval preprocessing using PreTreatment Module (PT Module) and Dewax and HIER Buffer H (pH 9; Epredia Catalog # TA-999-DHBH).Tissue was stained using the Alexa Fluor™ 647 Goat anti-Rat IgG Secondary Antibody at 1:200 at 37 ° Celsius for 2 minutes. (Yellow; Lunaphore Catalog # DR647RT) and counterstained with DAPI (blue; Lunaphore Catalog # DR100). Specific staining was localized to the membrane. Protocol available in COMET™ Panel Builder." class="big_thumb" />
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB600-1071SS | |||
| Azide and BSA Free | NBP2-80642 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-174SS | |||
| Azide and BSA Free | NBP2-80897 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB300-270SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-56674SS | |||
| Azide and BSA Free | NBP2-33241 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-111SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-24915SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB100-168SS | |||
| Azide and BSA Free | NBP2-80847 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NBP2-50037SS | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-108SS | |||
| Azide and BSA Free | NBP2-80674 | |||
| Formulation | Catalog # | Availability | Price | |
|---|---|---|---|---|
| BSA Free | NB200-114SS | |||
| Azide and BSA Free | NBP2-80854 | |||
![Immunocytochemistry/Immunofluorescence: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 antibody was tested in WEHI-3 cells with DyLight 488 (green). Nuclei and alpha-tubulin were counterstained with DAPI (blue) and DyLight 550 (red).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunocytochemistry-Immunofluorescence-NB600-1071-img0003.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse small intestine using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. This antibody specifically labelled the endothelial cells in blood vessels located primarily in the sub-mucosa, and of that of the mucosa muscularis and the mucosal lacteal.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0014.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - CD34 (MEC 14.7) antibody was tested at 1:250 in WEHI-3 cells with DyLight 488 (green) alongside a matched isotype control (black).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0002.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of CD34 on human renal cancer xenograft using CD34 antibody (clone MEC 14.7). The antibody detected the endothelial cells in the tumor vasculature which are originating from the host (mouse).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0005.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a human renal cancer tissue section using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The antibody did not detect human CD34 which is an expected outcome for this clone. This section was included in NB600-1071's IHC validation testing as a negative control.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0006.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody clone MEC 14.7 at 1:100 dilution. The signal was developed using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Notably, the antibody specifically stained the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0009.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of human renal cancer xenograft using CD34 antibody (clone MEC 14.7) at 1:100 dilution. The staining was detected using HRP-conjugated secondary antibody and DAB reagent followed by counterstaining of nuclei with hematoxylin. Note that this murine CD34 specific antibody stained only the endothelial cells of the tumor vasculature which is originating from the host animal cells (mouse). This observation was verified by including a negative control in this validation testing (see the IHC image of human renal cancer tissue section with negative signal for CD34).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0010.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse colon using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the colon.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0012.jpg)
![Immunohistochemistry-Paraffin: CD34 Antibody (MEC 14.7) [NB600-1071] - Analysis of a FFPE tissue section of mouse heart using rat anti-mouse CD34 (clone MEC 14.7) at 1:100 dilution. The signal was developed using HRP-conjugated anti-rat secondary with DAB reagent which followed counterstaining of nuclei using hematoxylin. The antibody specifically generated a staining of the endothelial cells in blood vessels of the heart tissue.](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Immunohistochemistry-Paraffin-NB600-1071-img0013.jpg)
![Flow Cytometry: CD34 Antibody (MEC 14.7) [NB600-1071] - An intracellular stain was performed on Raw264.7 cells with CD34 Antibody [MEC 14.7] NB600-1071 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature, followed by Rat IgG (H+L) Cross-Adsorbed Secondary Antibody, Dylight 488 (SA5-10018, Thermo Fisher).](http://images.novusbio.com/fullsize/CD34-Antibody-MEC-14-7-Flow-Cytometry-NB600-1071-img0015.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0011.jpg "Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Whole cell protein from mouse Neuro2A and MEF cells was separated on a 4-20% gel by SDS-PAGE, transferred to 0.2 um PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/mL anti-p19ARF in block buffer and detected with an anti-mouse HRP secondary antibody using chemiluminescence.")
![Immunohistochemistry: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Staining of sections from a wild type mouse testis taken at P11 were probed with NB200-174 (green). Sections were stained with DAPI to reveal the position of cell nuclei (blue).](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Immunohistochemistry-NB200-174-img0008.jpg)
![Flow (Intracellular): p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - An intracellular stain was performed on HEK293 cells with p14ARF (5-C3-1) antibody NB200-174 (blue) and a matched isotype control MAB0061 (orange) [A]. An intracellular stain was also performed on THP-1 (known homozygous deletion of gene, PMID: 19635138) cells to ensure antibody specificity [B]. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by Goat Anti-Rat F(ab)2 IgG (H+L) APC-conjugated Antibody (F0113, R&D Systems). *Note: This antibody recognizes both human (p14ARF) and mouse (p19ARF) versions of the protein.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Flow-Intracellular-NB200-174-img0010.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Analysis of endogenous p19Arf. Total cell lysates (25 ug) from NIH3T3 cells, which have deleted the Arf gene (Lanes 1) and from wild type mouse embryo fibroblasts (MEFs) at passage 6, which express p19Arf (Lanes 2), were resolved by SDS-PAGE.](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Western-Blot-NB200-174-img0005.jpg)
![<b>Genetic Strategies Validation. </b>Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (5-C3-1) [NB200-174] - Detection of p19Arf. Wild type mouse embryo fibroblasts (MEF) at passage 5 (panels 1, 2) and NIH3T3 cells, which have deleted the Arf gene (panels 3, 4) were probed with NB200-17 and nuclear stain (overlay in panels 2 and 4).](http://images.novusbio.com/fullsize/p19ARF-CDKN2A-Antibody-5-C3-1-Knockout-Validated-NB200-174-img0009.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Phosphorylation of NPM-Ser48 regulates the localization of NPM & p19A(A) Npm−/−, p53−/−double null MEF were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. Cells were fixed & stained with DAPI & anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates & whole cell lysates from Npm−/−;p53−/− MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed & stained with DAPI, anti-NPM & anti p19ARF. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-31020241621829.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416205122.jpg)
![Western Blot: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Loss of P19Arf enhances tumor growth & primary lung fibroblasts induce p19Arf in response to leucine deprivation (LD). (A) Graph of sarcoma (SKPY) tumor volume on the indicated days. SKPY cells were injected into the flank of WT & p19Arf-null mice. Tumor volume was measured by caliper. N=7 mice/WT cohort & N=15 mice/p19Arf−/− cohort. (B) Western blot for p19Arf protein expression in WT & Arf-null fibroblasts after LD for the indicated days. Densitometric quantification of p19Arf protein expression relative to beta -tubulin is shown on right. (C) qPCR for p19Arf mRNA in WT or p19Arf−/− fibroblasts during LD for the indicated days. (D) Representative immunofluorescence images for P19Arf subcellular localization on the indicated days after LD in WT or p19Arf−/− ALFs. Quantification of nuclear p19Arf is shown in graph on right. (E) Western blot analysis of phospho-eIF2 alpha (P-eIF2 alpha ) & total eIF2 alpha expression in WT & p19Arf-null murine ALFs during LD for the indicated days. Graph quantifies intensity of P-eIF2 alpha expression relative to day 0. beta -Tubulin used as loading control. (F) Western blot analysis of P-eIF2 alpha expression in WT & p19Arf−/− ALFs upon treatment with a GCN2 inhibitor (GCN2-IN-1; A-92 1 µM in DMSO) during overnight LD. Actin used as a loading control. Quantification of P-eIF2 alpha expression relative to total eIF2 alpha . N=3; *, P<0.05; ns, not significant. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/34994382), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416205128.jpg)
![Immunocytochemistry/ Immunofluorescence: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free [NB200-174] - Phosphorylation of NPM-Ser48 regulates the localization of NPM & p19A(A) Npm−/−, p53−/−double null MEF were infected with pBabe retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT or NPM-S48A as indicated. Cells were fixed & stained with DAPI & anti-NPM (left) or anti-phospho-S48-NPM (pS48-NPM). (B) NPM immunoprecipitates & whole cell lysates from Npm−/−;p53−/− MEFs expressing human NPM or NPM-S48A were probed with the indicated antibodies.(C) Graph, quantification of p19ARF staining intensity in confocal images using ImageJ. (D) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus expressing FLAG-tagged-myr-AKT1 in combination with NPM-WT, NPM-S48A or S48E as indicated. Cells were fixed & stained with DAPI, anti-NPM & anti p19ARF. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-310202416203717.jpg)
![Flow Cytometry: p19ARF/CDKN2A Antibody (5-C3-1) - BSA Free - Conducted the antibody trial with two different dilutions of p19ARF/CDKN2A Antibody (5-C3-1) [PE] (Catalog # NB200-174PE) (1:500 and 1:100) and compared them to an IgG control which was also PE labelled. Image from a verified customer review.](http://images.novusbio.com/fullsize/nb200-174_rat-monoclonal-p19arf-cdkn2a-antibody-5-c3-1-312202414314910.png)
![Simple Western: Park7/DJ-1 Antibody [NB300-270] - Simple Western lane view shows a specific band for Park7 (DJ-1) in 0.05 mg/ml of Human Brain lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/Park7-DJ-1-Antibody-Simple-Western-NB300-270-img0009.jpg "Simple Western: Park7/DJ-1 Antibody [NB300-270] - Simple Western lane view shows a specific band for Park7 (DJ-1) in 0.05 mg/ml of Human Brain lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.")
![Immunohistochemistry-Paraffin: Park7/DJ-1 Antibody [NB300-270] - Park7(DJ-1) detected in paraffin embedded human cortex.](http://images.novusbio.com/fullsize/Park7-DJ-1-Antibody-Immunohistochemistry-Paraffin-NB300-270-img0007.jpg)
![Western Blot: Park7/DJ-1 Antibody [NB300-270] - Human HEK293 cells and mouse brain lysates.](http://images.novusbio.com/fullsize/Park7-DJ-1-Antibody-Western-Blot-NB300-270-img0005.jpg)
![Western Blot: Park7/DJ-1 Antibody [NB300-270] - Cells were transfected with the pCMV6-ENTRY control (lane 1) or pCMV6-ENTRY PARK7 cDNA (lane 2) for 48 hrs and lysed. Equivalent amounts of cell lysates (5 ug per lane) were separated by SDS-PAGE and immunoblotted with anti-Park7(DJ-1).](http://images.novusbio.com/fullsize/Park7-DJ-1-Antibody-Western-Blot-NB300-270-img0008.jpg)
![Western Blot: Park7/DJ-1 Antibody [NB300-270] - Presence of oxDJ-1 in RPE cells subjected to oxidative stress.ARPE-19 monolayers were treated with increasing concentrations (0 to 800 µM) of H2O2 for 1 hr (A) & 18 hs (B), harvested, & analyzed by immunoblot assay with oxDJ-1 antibody (upper panel). Protein loadings were confirmed in replicate blots probed with GAPDH (lower panel). Each lane contained 20 µg of protein. A dose response is observed when cells are exposed to increasing concentrations of H2O2 for 1 h (A, lanes 1 to 6) & 18 hrs (B, lanes 7 to 12). Confocal immunofluorescence staining of baseline ARPE-19 cultures (C) fixed before extraction with Triton X-100 & labeling with oxDJ-1 antibodies revealed absence of oxDJ-1. However, oxDJ-1 is observed in the cytoplasm (arrows) & perinuclear area (arrowheads) of RPE cells exposure to 400 µM H2O2 for 1 h (D) & 18 hrs (E). Cell nuclei were labeled with TO-PRO-3. Scale bar = 20 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23844142), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-270_rabbit-polyclonal-park7-dj-1-antibody-31020241621815.jpg)
![Western Blot: Park7/DJ-1 Antibody [NB300-270] - Presence of oxDJ-1 in RPE cells subjected to oxidative stress.ARPE-19 monolayers were treated with increasing concentrations (0 to 800 µM) of H2O2 for 1 hr (A) & 18 hs (B), harvested, & analyzed by immunoblot assay with oxDJ-1 antibody (upper panel). Protein loadings were confirmed in replicate blots probed with GAPDH (lower panel). Each lane contained 20 µg of protein. A dose response is observed when cells are exposed to increasing concentrations of H2O2 for 1 h (A, lanes 1 to 6) & 18 hrs (B, lanes 7 to 12). Confocal immunofluorescence staining of baseline ARPE-19 cultures (C) fixed before extraction with Triton X-100 & labeling with oxDJ-1 antibodies revealed absence of oxDJ-1. However, oxDJ-1 is observed in the cytoplasm (arrows) & perinuclear area (arrowheads) of RPE cells exposure to 400 µM H2O2 for 1 h (D) & 18 hrs (E). Cell nuclei were labeled with TO-PRO-3. Scale bar = 20 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23844142), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-270_rabbit-polyclonal-park7-dj-1-antibody-3102024162185.jpg)
![Western Blot: Park7/DJ-1 Antibody [NB300-270] - Presence of oxDJ-1 in RPE cells subjected to oxidative stress.ARPE-19 monolayers were treated with increasing concentrations (0 to 800 µM) of H2O2 for 1 hr (A) & 18 hs (B), harvested, & analyzed by immunoblot assay with oxDJ-1 antibody (upper panel). Protein loadings were confirmed in replicate blots probed with GAPDH (lower panel). Each lane contained 20 µg of protein. A dose response is observed when cells are exposed to increasing concentrations of H2O2 for 1 h (A, lanes 1 to 6) & 18 hrs (B, lanes 7 to 12). Confocal immunofluorescence staining of baseline ARPE-19 cultures (C) fixed before extraction with Triton X-100 & labeling with oxDJ-1 antibodies revealed absence of oxDJ-1. However, oxDJ-1 is observed in the cytoplasm (arrows) & perinuclear area (arrowheads) of RPE cells exposure to 400 µM H2O2 for 1 h (D) & 18 hrs (E). Cell nuclei were labeled with TO-PRO-3. Scale bar = 20 µm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/23844142), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb300-270_rabbit-polyclonal-park7-dj-1-antibody-310202416212344.jpg)
![Immunohistochemistry-Paraffin: p73 Antibody (5B1288) [NB100-56674] - Human breast cancer section using 10ug/mL of p73 antibody (clone 5B1288) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10 mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). The cancer cells showed cytoplasmic immunoreactivity for p73 and the signal was very weak in the core and stroma of tumors. Peripheral cells of tumor areas, apparently the myoepithelial cells, showed a strong nuclear staining of p73.](http://images.novusbio.com/fullsize/p73-Antibody-5B1288-Immunohistochemistry-Paraffin-NB100-56674-img0008.jpg "Immunohistochemistry-Paraffin: p73 Antibody (5B1288) [NB100-56674] - Human breast cancer section using 10ug/mL of p73 antibody (clone 5B1288) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10 mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). The cancer cells showed cytoplasmic immunoreactivity for p73 and the signal was very weak in the core and stroma of tumors. Peripheral cells of tumor areas, apparently the myoepithelial cells, showed a strong nuclear staining of p73.")
![Immunohistochemistry-Paraffin: p73 Antibody (5B1288) [NB100-56674] - Human breast cancer section using 10 ug/mL of p73 antibody (clone 5B1288) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) with 10 mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching using peroxide block. The sections were incubated with primary antibody for 30 minutes. Bond Polymer Refine Detection (Leica Biosystems) and DAB were used for signal detection which followed counterstaining with hematoxylin. Whole slide scanning and capturing of representative images (20X) were performed using Aperio AT2 (Leica Biosystems). The cancer cells showed cytoplasmic immunoreactivity for p73 and the signal was very weak in the core and stroma of tumors. Peripheral cells of tumor areas, apparently the myoepithelial cells, showed a strong nuclear staining of p73.](http://images.novusbio.com/fullsize/p73-Antibody-5B1288-Immunohistochemistry-Paraffin-NB100-56674-img0009.jpg)
![Western Blot: p73 Antibody (5B1288) [NB100-56674] - Analysis of p73 in transfected cell lysate using this antibody.](http://images.novusbio.com/fullsize/p73-Antibody-5B1288-Western-Blot-NB100-56674-img0004.jpg)
![Western Blot: p73 Antibody (5B1288) [NB100-56674] - Analysis of p73 in HeLa cell lysate (Cat no. NBP2-25045) using this antibody at 1 ug/mL.](http://images.novusbio.com/fullsize/p73-Antibody-5B1288-Western-Blot-NB100-56674-img0006.jpg)
![Immunocytochemistry/Immunofluorescence: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested in HeLa cells with Dylight 488 (green). Nuclei were counterstained with DAPI (blue). Tubulin was stained with alpha tubulin (red).](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunocytochemistry-Immunofluorescence-NB200-111-img0006.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - ARF expression levels in OCI/AML3 cells after proteasome treatment. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0009.jpg)
![Flow Cytometry: p14ARF/CDKN2A Antibody [NB200-111] - p14ARF antibody was tested at 1:400 in HeLa cells using an Alexa Fluor 488 secondary (shown in purple). M1 is defined by unstained cells.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Flow-Cytometry-NB200-111-img0007.jpg)
![Western Blot: p14ARF/CDKN2A Antibody [NB200-111] - Analysis of HeLa Whole Cell Lysate (NB800-PC1) using p14ARF antibody (lot C) employing ECL detection method.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Western-Blot-NB200-111-img0008.jpg)
![Immunohistochemistry-Frozen: p14ARF/CDKN2A Antibody [NB200-111] - Mouse brain section, hippocampal (10 um thickness). 3% PFA perfused. 1:1000 dilultion. Image from verified customer review. Image using the Biotin form of this antibody.](http://images.novusbio.com/fullsize/p14ARF-CDKN2A-Antibody-Immunohistochemistry-Frozen-NB200-111-img0010.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203719.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212372.jpg)
![Immunocytochemistry/ Immunofluorescence: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT modulates p53 stability in-vivo & synergizes with ionizing radiation to inhibit tumor growth(A) PSN1 xenografts (PSN1 cells co-injected with LTC-14 stellate cells) established in the flank of athymic nude mice were treated with MK-2206 (60 mg/kg-320 mg/kg) as indicated or beta -cyclo-dextrin (1.5 mg/ml) carrier. Xenograft tumors were lysed & lysates probed by western blot with the indicated antibodies. (B-D) Sections of PSN1 xenografts treated with three consecutive doses of MK-2206 (60 mg/kg). (B) Sections of PSN1 xenografts & in-vitro PSN1 cells fixed & stained with anti-NPM (red) & anti-p14ARF (green). (C) PSN1 xenografts treated with MK-2206 or carrier were stained with DAPI, anti-p53 (DO1) or p53mut (OP29 clone) (D) PSN1 xenografts treated with MK-2206 (60 mg/kg) or carrier were stained by immunohistochemical methods with anti-pS473-AKT, anti-phospho-S48-NPM (pS48-NPM) or p53. (E) PSN1 xenografts established in the flank of athymic nude mice were injected subcutaneously with two alternate day doses of MK-2206 (60 mg/kg) or carrier. Mice were subsequently treated with a single dose of IR (6 Gy) & tumor volumes measured regularly with callipers. Dash lines indicate tumor growth differential at 250 mm3. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416203724.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT decreases p53mut stability(A) T24 cells & PSN1 cells were treated with MK-2206 (5 μM) or DMSO for 24 hrs. Cells were fixed & stained with DAPI & anti-mutant p53 (OP29 clone). (B) T24 cells were pre-treated with MK-2206 (5 μM) or DMSO for 24 hrs before the addition of fresh media containing cyclohexamide (100 μM) (CHX) in combination with MK-2206 (5 μM) or DMSO for the times indicated. Nuclear extracts were prepared from treated cells & blotted with the indicated antibodies. Quantification is relative to initiation of CHX treatment for both conditions *, MK-2206 is 40% of DMSO control but taken as 1.0 for relative assessment. (C) H1299 cells were transfected with HA-tagged-ubiquitin & mutant p53 (R175H or R248W) as indicated. Transfected cells were treated with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) for 16hrs as indicated. p53 immunoprecipitates & whole cell lysates were probed with the indicated antibodies. (D) T24 cells were transfected with non-targeting control or p14ARF siRNA & treated with DMSO, MK-2206 (5 μM) or the NPM oligomerisation inhibitor NCS348884 (4 μM) (Qi et al., 2008) as indicated. (E) T24 cells were transfected with non-targeting control, AKT1, or p14ARF siRNA. Cells were treated with NCS348884 (4 μM), Nutlin3A (5 μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. (F) KPC mice derived KRASG12D p53 Floxed (p53Fl), KRASG12D p53R172H ARF+/+ & KRASG12D p53R172H ARF−/− pancreatic tumor cells were treated with MK-2206 (1μM), Nutlin3A (5μM) or DMSO as indicated. Whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205197.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416212370.jpg)
![Western Blot: p14ARF/CDKN2A Antibody - BSA Free [NB200-111] - Inhibition of AKT promotes enhanced MDM2 activity via the increased association between NPM & p14ARF(A) Npm−/−, p53−/−double null MEF were infected with pBABE retrovirus empty vector & pBABE expressing FLAG-tagged-NPM-WT, NPM-S48A or S48E as indicated. Immunopurification of NPM was done by pulling down with the Flag tag (middle panel) followed by elution of complexes by the Flag peptide & subsequent immunopurification of endogenous MDM2 (lower panel). (B) Nuclear immunoprecipitates of MDM2 from T24 cells treated with MK-2206 (5 μM, 24 hrs). Immunoprecipitates & lysates were blotted with the indicated antibodies. (C) T24 cells were treated with MK-2206 (5 μM) as indicated. p14ARF was immunoprecipitated from whole cell lysates & nuclear extracts & the association with NPM & MDM2 determined by western blot. Immunoprecipitates & lysates were blotted with the indicated antibodies. (D) MDM2 & (E) p53 ubiquinitation assay in H1299 cells transfected with wild type p53, HA-tagged ubiquitin & treated for 16 hrs with DMSO, MK-2206 (5 μM) or Nutlin3A (5 μM) as indicated. Immunoprecipitates & whole cell lysates were probed with the indicated antibodies. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/25071014), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-111_rabbit-polyclonal-p14arf-cdkn2a-antibody-310202416205120.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Bovine ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0006.jpg "Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Bovine ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.")
![Immunohistochemistry-Paraffin: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Analysis of Superoxide Dismutase 1 in FFPE human liver tissue using an isotype control (top) and NBP2-24915 (bottom) at 5 ug/ml.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Immunohistochemistry-Paraffin-NBP2-24915-img0003.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Analysis of SOD in liver lysate of 1) human, 2) mouse, and 3) rat using this antibody. 025 ug/ml.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0004.jpg)
![Western Blot: SOD1/Cu-Zn SOD Antibody [NBP2-24915] - Human ocular fluid. Antibody at 1:1000. Western blot image submitted by a verified customer review.](http://images.novusbio.com/fullsize/SOD1-Cu-Zn-SOD-Antibody-Western-Blot-NBP2-24915-img0005.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - Detection of Human and Mouse DDX6 by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-DDX6 antibody NB200-192 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.](http://images.novusbio.com/fullsize/DDX6-Antibody-Western-Blot-NB200-192-img0009.jpg "Western Blot: DDX6 Antibody [NB200-192] - Detection of Human and Mouse DDX6 by Western Blot. Samples: Whole cell lysate (50 ug) from HeLa, 293T, and mouse NIH3T3 cells prepared using NETN lysis buffer. Antibody: Affinity purified rabbit anti-DDX6 antibody NB200-192 used for WB at 0.1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.")
![Immunohistochemistry-Paraffin: DDX6 Antibody [NB200-192] - FFPE section of human colon carcinoma. Antibody: Affinity purified rabbit anti-DDX6 (left) and Lot 3 (right) used at a dilution of 1:1,000 (1ug/ml). Detection: DAB. Counterstain: IHC Hematoxylin (blue).](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunohistochemistry-Paraffin-NB200-192-img0008.jpg)
![<b>Independent Antibodies Validation. </b>Immunoprecipitation: DDX6 Antibody [NB200-192] - Detection of human DDX6 by western blot of immunoprecipitates. Samples: Whole cell lysate (0.5 or 1.0 mg per IP reaction; 20% of IP loaded) from HeLa cells prepared using NETN lysis buffer. Antibodies: Affinity purified rabbit anti-DDX6 antibody NB200-192 (lot NB200-192-3) used for IP at 6 ug per reaction. DDX6 was also immunoprecipitated by a previous lot of this antibody (NB200-192-2) and rabbit anti-DDX6 antibody NB200-191. For blotting immunoprecipitated DDX6, NB200-192 was used at 1 ug/ml. Detection: Chemiluminescence with an exposure time of 1 second.](http://images.novusbio.com/fullsize/DDX6-Antibody-Immunoprecipitation-NB200-192-img0010.jpg)
![Immunocytochemistry/ Immunofluorescence: DDX6 Antibody [NB200-192] - 5-FU-induced SG assembly is rescued by interfering with RNA incorporation. HeLa cells were treated with 1 mM Urd, 0.1 mM 5-FU or both, as well as with 1 μM FUrd or a combination of 1 μM FUrd & 10 μM Urd. Localization of SG marker protein TIAR (green) & SG/P-body marker protein DDX6 (red) was investigated. Nuclei were stained with Hoechst. Scale bars represent 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24728989), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202415363749.jpg)
![Immunocytochemistry/ Immunofluorescence: DDX6 Antibody [NB200-192] - 5-FU-induced SG assembly depends on RNA incorporation. (A) Schematic representation of the cellular 5-FU metabolism leading to incorporation of the different metabolites into RNA or DNA. (B) HeLa cells were treated with two concentrations of the 5-FU metabolites FUrd or FdUrd for 72 h. SG marker protein TIAR (green) & SG/P-body marker protein DDX6 (red) were visualized. Nuclei were stained with Hoechst. Scale bars represent 20 μm. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/24728989), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202415371964.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - HNRNPK is necessary for DDX6 to bind differentiation associated mRNAs. a RNA IP was performed in CTLi & HNRNPKi cells using a DDX6 antibody. RT-QPCR was used to determine the levels of binding between DDX6 & differentiation associated mRNAs in the presence or absence of HNRNPK. IGG IPs in CTLi & HNRNPKi cells were used as specificity controls. Binding was calculated as a percent of input. b RNA IP was performed in CTLi & DDX6i cells using a HNRNPK antibody. RT-QPCR was used to determine the levels of binding between HNRNPK & differentiation associated mRNAs in the presence or absence of DDX6. IGG IPs in CTLi & DDX6i cells were used as specificity controls. n = 4. c Western blot analysis of HNRNPK & DDX6 protein levels upon HNRNPK or DDX6 knockdown. d Immunoprecipitations (IPs) were performed using either an HNRNPK or DDX6 antibody or IGG & Western blotted for HNRNPK or DDX6 protein expression. IPs were performed +/− RNase A. Five percent of the cell lysate was used as input. Representative blots are shown. n = 3 independent experiments performed for Fig. 3 unless otherwise indicated. All error bars = SD. ****p < 0.0001, ***p < 0.001 (2 way ANOVA followed by Tukey’s multiple comparison test for a, b) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31519929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202416212349.jpg)
![Western Blot: DDX6 Antibody [NB200-192] - HNRNPK is necessary for DDX6 to bind differentiation associated mRNAs. a RNA IP was performed in CTLi & HNRNPKi cells using a DDX6 antibody. RT-QPCR was used to determine the levels of binding between DDX6 & differentiation associated mRNAs in the presence or absence of HNRNPK. IGG IPs in CTLi & HNRNPKi cells were used as specificity controls. Binding was calculated as a percent of input. b RNA IP was performed in CTLi & DDX6i cells using a HNRNPK antibody. RT-QPCR was used to determine the levels of binding between HNRNPK & differentiation associated mRNAs in the presence or absence of DDX6. IGG IPs in CTLi & DDX6i cells were used as specificity controls. n = 4. c Western blot analysis of HNRNPK & DDX6 protein levels upon HNRNPK or DDX6 knockdown. d Immunoprecipitations (IPs) were performed using either an HNRNPK or DDX6 antibody or IGG & Western blotted for HNRNPK or DDX6 protein expression. IPs were performed +/− RNase A. Five percent of the cell lysate was used as input. Representative blots are shown. n = 3 independent experiments performed for Fig. 3 unless otherwise indicated. All error bars = SD. ****p < 0.0001, ***p < 0.001 (2 way ANOVA followed by Tukey’s multiple comparison test for a, b) Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/31519929), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb200-192_rabbit-polyclonal-ddx6-antibody-310202416205119.jpg)
![Western Blot: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT in MCF7 lysate using NB100-168 at 1:1000 dilution.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Western-Blot-NB100-168-img0002.jpg "Western Blot: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT in MCF7 lysate using NB100-168 at 1:1000 dilution.")
![Immunocytochemistry/Immunofluorescence: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT (Green) in Hela cells using NB100-168 at a 1:50 dilution. Nuclei (Blue) are counterstained using Hoechst 33258.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Immunocytochemistry-Immunofluorescence-NB100-168-img0004.jpg)
![Immunohistochemistry-Paraffin: MGMT Antibody (MT 23.2) [NB100-168] - IHC analysis of a formalin fixed paraffin-embedded (FFPE) human kidney using 1:2000 conc. of MGMT antibody (clone MT 23.2) on a Bond Rx autostainer (Leica Biosystems). The assay involved 20 minutes of heat induced antigen retrieval (HIER) using 10mM sodium citrate buffer (pH 6.0) and endogenous peroxidase quenching with peroxide block. The sections were incubated with primary antibody for 30 minutes and Bond Polymer Refine Detection (Leica Biosystems) with DAB was used for signal development followed by counterstaining with hematoxylin. Whole slide scanning and capturing of representative images was performed using Aperio AT2 (Leica Biosystems). Nuclear staining of MGMT was observed. Staining was performed by Histowiz.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Immunohistochemistry-Paraffin-NB100-168-img0013.jpg)
![Flow Cytometry: MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on HeLa cells with MGMT Antibody (MT 23.2) antibody NB100-168 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) PE-conjugated secondary antibody (F0102B, R&D Systems).](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Cytometry-NB100-168-img0015.jpg)
![Immunocytochemistry/Immunofluorescence: MGMT Antibody (MT 23.2) [NB100-168] - MCF7 cells were fixed for 10 minutes using 10% formalin and then permeabilized for 5 minutes using 1X TBS + 0.5% Triton-X100. The cells were incubated with anti-MGMT (MT 23.2) NB100-168 at a 1:200 dilution overnight at 4C and detected with an anti-mouse Dylight 488 (Green) at a 1:500 dilution. Actin was counterstained with Phalloidin 568 (Red) at a 1:200 dilution. Nuclei were counterstained with DAPI (Blue). Cells were imaged using a 40X objective.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Immunocytochemistry-Immunofluorescence-NB100-168-img0006.jpg)
![Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Jurkat cells with MGMT Antibody (MT 23.2) antibody NB100-168 (blue) and a matched isotype control NBP2-27231 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 1 ug/mL for 30 minutes at room temperature, followed by mouse F(ab)2 IgG (H+L) APC-conjugated secondary antibody (F0101B, R&D Systems).](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Intracellular-NB100-168-img0008.jpg)
![Flow Cytometry: MGMT Antibody (MT 23.2) [NB100-168] - Detection of MGMT in Human Jurkat Cell Line by Flow Cytometry. Human Jurkat cell line was stained with Mouse Anti- MGMT Monoclonal Antibody (Catalog # NB100-168, filled histogram), or Mouse IgG2B isotype control (Catalog # MAB0041, open histogram) followed by APC-conjugated Anti-Mouse IgG Secondary Antibody (Catalog # F0101B). To facilitate intracellular staining, cells were fixed with FlowX FoxP3 Fixation & Permeabilization Buffer Kit (Catalog # FC012).<br/>Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Cytometry-NB100-168-img0011.jpg)
![Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Raji cells with MGMT Antibody (MT 23.2) antibody NB100-168AF647 (blue) and a matched isotype control NBP2-27231AF647 (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Intracellular-NB100-168-img0012.jpg)
![Flow (Intracellular): MGMT Antibody (MT 23.2) [NB100-168] - An intracellular stain was performed on Jurkat cells with MGMT Antibody (MT 23.2) antibody NB100-168AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeablized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Flow-Intracellular-NB100-168-img0014.jpg)
![Simple Western: MGMT Antibody (MT 23.2) [NB100-168] - Simple Western lane view shows a specific band for MGMT in 0.2 mg/ml of MCF-7 lysate. This experiment was performed under reducing conditions using the 12-230 kDa separation system.](http://images.novusbio.com/fullsize/MGMT-Antibody-MT-23-2-Simple-Western-NB100-168-img0005.jpg)
![Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0003.jpg "<b>Biological Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Top panel: Analysis of c-Fos expression in HeLa cells using NBP2-50037. Lane 1: HeLa cells were serum-starved for 36 hours. Lane 2: Serum-starved HeLa cells were stimulated with 20% FBS (fetal bovine serum) for 2 hours. NBP2-50037 recognizes bands in the range of 50-65 kDa, which represent multiple forms of c-Fos. Serum starvation attenuates c-Fos expression, while 20% FBS strongly stimulates c-Fos expression. Bottom panel: Blot was stripped and probed with monoclonal antibody against GAPDH (NB300-221) used as loading control.")
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Section of rat hippocampus stained with mouse monoclonal antibody to c-FOS NBP2-50037 in red and counterstained with rabbit polyclonal antibody to FOX3/NeuN. DAPI reveals nuclei of neurons and glia in blue. The hippocampal neurons stain green for FOX3/NeuN and a few also are expressing c-FOS, and so appear orange. These cells were spontaneously active at the time the animal was sacrificed.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0006.jpg)
![<b>Genetic Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Western blot shows lysates of HeLa human cervical epithelial carcinoma parental cell line and c-Fox knockout (KO) HeLa cell line. PVDF membrane was probed with 1:1000 of Mouse Anti-Human c-Fox Monoclonal Antibody (Catalog # NBP2-50037) followed by HRP-conjugated Anti-Mouse IgG Secondary Antibody (Catalog #HAF018). Specific band was detected for c-Fox at approximately 52 kDa (as indicated) in the parental HeLa cell line, but is not detectable in the knockout HeLa cell line. This experiment was conducted under reducing conditions.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Knockout-Validated-NBP2-50037-img0005.jpg)
![<b>Biological Strategies Validation. </b>Western Blot: c-Fos Antibody (2H2) [NBP2-50037] - Analysis of cell lysates using mouse c-Fos mAb, dilution 1:1,000 (Green), and rabbit GAPDH pAb, dilution 1:20,000 (Red) used as a loading control. [1] protein standard (red), [2] HeLa cells in serum free media. [3] HeLa cells stimulated with 20% fetal bovine serum for 2hrs after 36hrs in serum free media. [4] rat cortical neurons. [5] rat cortical neurons treated with membrane depolarization buffer for 5hrs. Multiple bands at 50-65kDa in stimulated or treated cell lysates correspond to different forms of the c-Fos proten. The single band at 37 kDa represents GAPDH protein.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Western-Blot-NBP2-50037-img0007.jpg)
![Immunohistochemistry: c-Fos Antibody (2H2) [NBP2-50037] - pAb 1:1000 (green), DAPI counterstain (blue) on 30 micron cryosection of mouse spinal cord. This image was submitted via customer Review.](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-NBP2-50037-img0004.jpg)
![<b>Biological Strategies Validation. </b>Immunocytochemistry/Immunofluorescence: c-Fos Antibody (2H2) [NBP2-50037] - Left: NBP2-50037 staining (green) in HeLa cells, which were treated with serum-starvation for 36 hrs, followed by 2 hrs 20% FBS stimulation (bottom), or PBS treatment (top). Green c-Fos staining only localizes in the nuclei of stimulated cells, but not in un-stimulated cells. Cells are counter-stained with chicken pAb against Vimentin (NB300-223, red). Blue shows DAPI staining of nucleus. Middle: Mouse brain section (45 uM; fixed by transcardial perfusion with 4% PFA) labeled with NBP2-50037 using a standard HRP-DAB staining technique. Cells expressing c-Fos show dark color in nucleus. Right: Mouse cortical section labeled with NBP2-50037 (red) and rabbit polyclonal anti-NeuN (NBP1-92716, green) using IF confocal. Neurons positive for c-Fos and RBFOX3/NeuN appear to be yellow. Inset shows an enlarged image of NBP2-50037 staining. Nuclei are labeled with Dapi (blue).](http://images.novusbio.com/fullsize/c-Fos-Antibody-2H2-Immunocytochemistry-Immunofluorescence-NBP2-50037-img0001.jpg)
![Western Blot: ATM Antibody (5C2) [NB100-220] - HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody (5C2) [NB100-220] diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced. Observed molecular weight ~320 kDa. Theoretical molecular weight 351 kDa.](http://images.novusbio.com/fullsize/ATM-Antibody-5C2-Western-Blot-NB100-220-img0007.jpg "Western Blot: ATM Antibody (5C2) [NB100-220] - HeLa whole cell and nuclear extracts (30 ug) were separated by 5% SDS-PAGE, and the membrane was blotted with ATM antibody (5C2) [NB100-220] diluted at 1:1000. The HRP-conjugated anti-mouse IgG antibody [NBP2-19382] was used to detect the primary antibody, and the signal was developed with Trident ECL plus-Enhanced. Observed molecular weight ~320 kDa. Theoretical molecular weight 351 kDa.")
![Immunocytochemistry/Immunofluorescence: ATM Antibody (5C2) [NB100-220] - HeLa cells were fixed in 4% paraformaldehyde at RT for 15 min. Green: ATM protein stained by ATM antibody (5C2) [NB100-220] diluted at 1:200. Blue: Hoechst 33342 staining. Scale bar = 10 um.](http://images.novusbio.com/fullsize/ATM-Antibody-5C2-Immunocytochemistry-Immunofluorescence-NB100-220-img0004.jpg)
![Western Blot: ATM Antibody (5C2) [NB100-220] - Absence of Atm does not relieve the selective pressure to inactivate p53 during chemical carcinogenesis.A. Representative images of 3MC-fibrosarcomas immunostained for Arf, p53 & p21 (see also Table 1). The upper & middle rows are representative of the large majority of fibrosarcomas developed in wild-type (upper) & Atm-null (middle) mice, which are consistent with a mutant p53 (i.e. strongly positive for p53 & negative for p21). The lower row is representative of the fibrosarcomas developed in Arf-null mice, which are consistent with a functional p53 (i.e. very weakly positive for p53 & positive for p21). B. Examples of cancer cell lines established from 3MC-fibrosarcomas (each line derives from an independent fibrosarcoma). The genotype of the mice where the 3MC-fibrosarcomas were generated is indicated, as well as, the status of p53 as determined by a nutlin-sensitivity assay (see Supplementary Figures S5 & S6). Cell lines were exposed to 10 Gy & protein extracts were obtained 1h & 24h after irradiation. The levels of the indicated proteins were determined by immunoblotting using beta -actin as loading control. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/19421407), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-31020241612655.jpg)
![Immunohistochemistry: ATM Antibody (5C2) [NB100-220] - Limited role of Atm in p53-mediated tumor suppression & DNA damage response in chemically-induced fibrosarcomas.A. Mice of the indicated genotypes, wt (n = 15), p53-super (n = 16), Atm-null (n = 9), p53-super/Atm-null (n = 13) & Arf-null (n = 12), were injected intramuscularly with 3-methyl-cholanthrene (3MC) & tumour development was monitored. Kaplan-Meier tumour-free curves were obtained & statistical significant differences (logrank test) were found for wt vs. p53-super (p<0.005), Atm-null vs. p53-super/Atm-null (p<0.001) & Arf-null vs. wt (p<0.0001). No significant differences were found for wt vs. Atm-null (p = 0.11), or p53-super vs. p53-super/Atm-null (p = 0.18). B. Quantification of the persistent DNA damage response ( gamma H2AX), proliferation (Ki67), & apoptosis (activated caspase-3) in 3MC-fibrosarcomas generated in mice of the indicated genotypes. Quantifications are relative to the 3MC-fibrosarcomas in wild-type mice. Values correspond to the average & standard deviation (n = 5 per genotype). Examples of the immunostainings are shown in the panels at the right. Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/19421407), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-3102024165717.jpg)
![Immunocytochemistry/ Immunofluorescence: ATM Antibody (5C2) [NB100-220] - BAG3P209L aggregation leads to co-aggregation of proteasomal substrates. a Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT or FLAG-BAG3P209L using antibodies against BAG3 (green) or ubiquitin (red). Scale bar = 5 μm. b Suppression of GFP-HttQ74 aggregation of cells expressing a control, FLAG-BAG3WT or FLAG-BAG3P209L. Western blot against indicated antibodies is shown. c Quantification of GFP-HttQ74 aggregation of experiments similar to b. Relative percentage of SDS-insoluble protein levels are shown. Data represents the mean & standard deviation of three independent experiments. d Immunofluorescence pictures of HeLa cells expressing FLAG-BAG3WT or FLAG-BAG3P209L using antibodies against BAG3 (green) or ubiquitin (red). Left column BAG3, middle column ubiquitin & right column is the merge of BAG3 (green), ubiquitin (red), & DAPI (blue). Scale bar = 5 μm. e Fractionation of HEK293 cells expressing HSPB8, a control or BAG3WT or BAG3P209L, together with either Ub-R-GFP or GFP-ODC (ornithine decarboxylase). Western blot against GFP, FLAG (BAG3), Myc (HSPB8), & tubulin are shown. f Fractionation of HEK293 cells expressing HSPB8 & indicated BAG3 variants. Western blot using ubiquitin (FK2) & tubulin antibodies are shown. The same samples as in Fig. 5e have been used, loading control is therefore the same. Source data are provided as a Source data file Image collected & cropped by CiteAb from the following publication (//pubmed.ncbi.nlm.nih.gov/30559338), licensed under a CC-BY license. Not internally tested by Novus Biologicals.](http://images.novusbio.com/fullsize/nb100-220_mouse-monoclonal-atm-antibody-5c2-31020241553206.jpg)
![<b>Biological Strategies Validation. </b>Immunohistochemistry-Paraffin: c-Myc Antibody (9E11) [NB200-108] - c-Myc was detected in immersion fixed paraffin-embedded sections of human breast cancer using anti-human mouse monoclonal antibody (Catalog # NB200-108, clone 9E11) at 1:600 dilution overnight at 4C. Tissue was stained using the VisuCyte anti-mouse HRP polymer detection reagent (Catalog # VC001) with DAB chromogen (brown) and counterstained with hematoxylin (blue).<br/>Images may not be copied, printed or otherwise disseminated without express written permission of Novus Biologicals a bio-techne brand.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Immunohistochemistry-Paraffin-NB200-108-img0007.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U937 cells with c-Myc [9E11] Antibody NB200-108AF594 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 594.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0014.jpg)
![Western Blot: c-Myc Antibody (9E11) [NB200-108] - Whole cell protein from PC3 (lane 1), U-2 OS (lane 2) and mouse testis (lane 3) was separated on a 12% gel by SDS-PAGE, transferred to PVDF membrane and blocked in 5% non-fat milk in TBST. The membrane was probed with 2.0 ug/ml anti-c-Myc in 1% milk, and detected with an anti-mouse HRP secondary antibody using chemiluminescence.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Western-Blot-NB200-108-img0006.jpg)
![Flow (Intracellular): c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E11) NB200-108AF647 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Alexa Fluor 647.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Intracellular-NB200-108-img0008.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody (9E11) NB200-108PE (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 2.5 ug/mL for 30 minutes at room temperature. Both antibodies were conjugated to Phycoerthrin.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0009.jpg)
![Flow Cytometry: c-Myc Antibody (9E11) [NB200-108] - An intracellular stain was performed on U-937 cells with c-Myc Antibody [9E11] NB200-108 (blue) and a matched isotype control (orange). Cells were fixed with 4% PFA and then permeabilized with 0.1% saponin. Cells were incubated in an antibody dilution of 1.0 ug/mL for 30 minutes at room temperature, followed by Mouse IgG (H+L) Cross-Adsorbed Secondary Antibody.](http://images.novusbio.com/fullsize/c-Myc-Antibody-9E11-Flow-Cytometry-NB200-108-img0010.jpg)
![Western Blot: MMP-2 Antibody (8B4) - (Pro and Active) [NB200-114] - Analysis of MMP2 expression in ProMMP2 (1), Active MMP2 (2) and human pressure ulcer biopsy (3).](http://images.novusbio.com/fullsize/MMP-2-Antibody-8B4-Pro-and-Active-Western-Blot-NB200-114-img0005.jpg "Western Blot: MMP-2 Antibody (8B4) - (Pro and Active) [NB200-114] - Analysis of MMP2 expression in ProMMP2 (1), Active MMP2 (2) and human pressure ulcer biopsy (3).")
![Immunohistochemistry-Paraffin: MMP-2 Antibody (8B4) - (Pro and Active) [NB200-114] - Detection of MMP-2 staining in FFPE human ovary tissue. Primary antibody was used at 2.5 ug/ml with the avidin-biotin-peroxidase detection method.](http://images.novusbio.com/fullsize/MMP-2-Antibody-8B4-Pro-and-Active-Immunohistochemistry-Paraffin-NB200-114-img0006.jpg)
